Dyne Therapeutics, Inc. financial data

Symbol
DYN on Nasdaq
Industry
Pharmaceutical Preparations
Location
1560 Trapelo Road, Waltham, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.47K % +62.8%
Debt-to-equity 11.3 % -51.3%
Return On Equity -57.5 % +41.1%
Return On Assets -51.6 % +34.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 102M shares +65.8%
Common Stock, Shares, Outstanding 102M shares +65.9%
Entity Public Float 504M USD +133%
Common Stock, Value, Issued 10K USD +66.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 258M USD +39.6%
General and Administrative Expense 56M USD +89.8%
Operating Income (Loss) -314M USD -46.5%
Net Income (Loss) Attributable to Parent -295M USD -41.5%
Earnings Per Share, Basic -3.57 USD/shares +0.28%
Earnings Per Share, Diluted -3.57 USD/shares +0.28%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 532M USD +308%
Assets, Current 736M USD +338%
Property, Plant and Equipment, Net 4.9M USD -4.23%
Operating Lease, Right-of-Use Asset 25.6M USD -13.4%
Assets 769M USD +275%
Accounts Payable, Current 6.16M USD +73.3%
Employee-related Liabilities, Current 11.3M USD +89%
Liabilities, Current 43.3M USD +45.7%
Operating Lease, Liability, Noncurrent 20M USD -14.8%
Liabilities 63.3M USD +19%
Accumulated Other Comprehensive Income (Loss), Net of Tax 478K USD
Retained Earnings (Accumulated Deficit) -860M USD -52%
Stockholders' Equity Attributable to Parent 706M USD +364%
Liabilities and Equity 769M USD +275%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -78.5M USD -67.4%
Net Cash Provided by (Used in) Financing Activities 408M USD +1317%
Net Cash Provided by (Used in) Investing Activities -180M USD -765%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 102M shares +65.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 150M USD +1573%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 534M USD +303%
Deferred Tax Assets, Valuation Allowance 146M USD +28.3%
Deferred Tax Assets, Gross 152M USD +24%
Operating Lease, Liability 27.4M USD -10.1%
Payments to Acquire Property, Plant, and Equipment 191K USD -17%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -294M USD -41.9%
Lessee, Operating Lease, Liability, to be Paid 32.8M USD -12.6%
Property, Plant and Equipment, Gross 11.4M USD +14%
Operating Lease, Liability, Current 4.81M USD +2.14%
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.99M USD +3.01%
Lessee, Operating Lease, Liability, to be Paid, Year One 4.85M USD +2.41%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 5.36M USD -23.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.14M USD +3%
Deferred Tax Assets, Operating Loss Carryforwards 57.5M USD -4.21%
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.3M USD +2.99%
Additional Paid in Capital 1.57B USD +118%
Depreciation, Depletion and Amortization 1.65M USD +4.9%
Deferred Tax Assets, Net of Valuation Allowance 6.01M USD -31.7%
Share-based Payment Arrangement, Expense 41.1M USD +128%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%